Board Meeting24 Jul 2026, 05:40 pm
Astonea Labs Approves Audited Consolidated Financial Results for FY26
AI Summary
Astonea Labs Limited announced the outcome of its Board Meeting held on July 24, 2026. The Board approved the Audited Consolidated Financial Results for the half-year and financial year ended March 31, 2026. The approval was delayed due to the pending audit report of its associate company, Damaira Pharmaceuticals Private Limited. The Board also approved the Board's Report and the Annual Report for the financial year 2025-26. The trading window for securities will reopen 48 hours after the declaration of these results.
Key Highlights
- Approved Audited Consolidated Financial Results for FY ended March 31, 2026.
- Board's Report and Annual Report for FY 2025-26 also approved.
- Consolidated results approval delayed due to associate company audit.
- Trading window to reopen 48 hours post results declaration.
Price Impact
More from ASTONEALAB